证券代码：603456 证券简称：九洲药业 公告编号：2025-038 浙江九洲药业股份有限公司 关于注销部分已回购股份的实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：浙江九洲药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 10 日、5 月 8 日召开第八届董事会第十三次会议、2024 年年度股东 大会，审议通过《关于变更回购股份用途并注销的议案》，同意公司将 2024 年股 份回购方案用途由"用于后续实施股权激励计划"变更为"用于注销并减少公司 注册资本"，即对回购专用证券账户中 2024 年股份回购方案的 5,789,800 股库存 股进行注销并相应减少注册资本。 本次注销股份的有关情况 | 回购专用证券账户 | 本次注销 | 注销日期 | | | --- | --- | --- | --- | | 股份数量（股） | 股份数量（股） | | | | 13,525,800 | 5,789,800 2025 | 年 月 6 | 日 26 | 公司分别于 2025 年 ...

Core Viewpoint - The legal opinion letter from Zhejiang Tiance Law Firm confirms the legality and compliance of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.'s differentiated equity distribution plan for the year 2024, ensuring that the interests of the company and all shareholders are not harmed [6][10]. Group 1: Differentiated Equity Distribution - The differentiated equity distribution is necessitated by the company's share repurchase plan, which involves using self-owned funds to buy back shares for future employee incentive plans [6][7]. - As of May 22, 2025, the total share capital of the company is 895,235,828 shares, with 13,525,800 shares held in the repurchase account, which will not participate in the profit distribution [6][7]. - The company plans to distribute a cash dividend of 3.00 yuan (including tax) for every 10 shares, totaling 265,760,198.40 yuan (including tax) to shareholders, excluding the shares in the repurchase account [6][7]. Group 2: Legal Compliance and Verification - The law firm has conducted thorough verification of the documents and materials provided by the company, ensuring their authenticity and completeness, and has adhered to legal responsibilities and principles of diligence and good faith [2][3]. - The law firm emphasizes that the legal opinion is limited to legal issues related to the differentiated equity distribution and does not cover accounting or auditing matters [3][4]. - The law firm concludes that the differentiated equity distribution complies with relevant laws and regulations, including the Company Law and Securities Law, and does not harm the interests of the company or its shareholders [10].

Core Points - The company announced a cash dividend of 0.30 CNY per share for A shares [1][5] - The dividend distribution plan was approved at the annual general meeting on May 8, 2025 [2][3] - The total cash dividend distribution amounts to approximately 264.51 million CNY, representing 60.33% of the net profit attributable to shareholders for the fiscal year 2024 [2][3] Dividend Distribution Details - The record date for the dividend is June 18, 2025, with the last trading day on June 19, 2025, and the ex-dividend date also on June 19, 2025 [1][4] - The total share capital as of April 10, 2025, is 895,235,828 shares, with 9,368,500 shares in the repurchase account excluded from the dividend distribution [2][3] - The cash dividend will be distributed to shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [5][6] Taxation Information - Individual shareholders will not have personal income tax withheld at the time of dividend distribution, with a net cash dividend of 0.30 CNY per share [6][7] - For individual shareholders holding shares for less than one month, the effective tax rate on dividend income is 20%, while for those holding between one month and one year, it is 10% [6][7] - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in a net cash dividend of 0.27 CNY per share [6][7]

浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2024 年度差异化权益分派事项的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 0 法律意见书 浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2024 年度差异化权益分派事项的 法律意见书 编号：TCYJS2025H0852 号 致：浙江九洲药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司（以 下简称"九洲药业"或"公司"）的委托，就公司 2024 年度利润分配方案所涉及 的差异化权益分派（以下简称"本次差异化权益分派"）相关事宜，根据《中华人 民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司股份回购规则（2025 修订）》（以下简称 "《回购规则》"）和《上海证券交易所上市公司自律监管指引第 7 号——回购股 份（2025 年 3 月修订）》（以下简称"《自律监管指引第 7 号》"）等有关法律、 法规和有关规范性文件，出具本法律意见书。 第一部分 声 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-037 浙江九洲药业股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.30元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/18 | － | 2025/6/19 | 2025/6/19 | 差异化分红送转：是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 8 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《中华人民共和国公司法》（以下简称"公司法"）、《中华人民共和国证券法》（以下 简称"证券法"）、《上海证券交易所上市公司自律监管指引第 ...

Group 1 - The mutual recognition arrangement between the General Administration of Customs of China and the General Customs Administration of Mongolia for AEO (Authorized Economic Operator) enterprises was officially implemented on June 1, enhancing trade facilitation between the two countries [1] - AEO enterprises will benefit from lower document review rates, reduced import inspection rates, priority inspection for goods requiring physical checks, and designated customs liaison officers to assist with customs issues [1] - Zhejiang AnDe Electric Co., Ltd., a high-end kitchen appliance manufacturer, reported a 150% year-on-year increase in exports to Mongolia, amounting to 1.99 million yuan in 2024, attributing this growth to the AEO certification and the new mutual recognition arrangement [1] Group 2 - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. expressed optimism about the AEO mutual recognition arrangement, highlighting its alignment with the company's strategic goals to enhance product competitiveness and reduce international logistics costs [2] - In the first four months of this year, Zhejiang Province's trade with Mongolia reached 520 million yuan, a 39.3% increase year-on-year, with AEO enterprises in Hangzhou contributing 25.43 million yuan, a 59.6% increase [2] - The Hangzhou Customs plans to strengthen the cultivation of AEO enterprises, prioritizing certification for "Zhejiang Export Brand" companies and key industry chain enterprises to enhance their competitiveness and modern management systems [2] Group 3 - China has signed AEO mutual recognition agreements with 31 economies globally, covering 57 countries and regions, including 38 countries involved in the Belt and Road Initiative, leading the world in both the number of agreements and participating countries [3]

Group 1 - The overall market experienced a decline in the afternoon, but the pharmaceutical and medical sectors showed resilience, with only three out of 31 industries reporting gains [1] - The representative medical ETF (512170) saw a daily increase of 0.62%, with a significant trading volume of 9.82 billion, marking a 128% increase from the previous day and the highest single-day trading volume in over a month and a half [2] - The CXO-related stocks were the main contributors to the sector's performance, with notable gains from companies like Tigermed, which rose by 5.64%, while major player WuXi AppTec experienced a decline [2] Group 2 - For the week of May 19-23, the medical ETF (512170) accumulated a gain of 1.24%, outperforming major indices such as the Shanghai Composite Index, which fell by 0.57% [4] - The market for medical stocks is gradually recovering, with increased trading activity and positive catalysts such as domestic pharmaceutical companies securing overseas contracts [4] - A new "Pharmaceutical ETF" is set to launch on May 26, which will track the CSI Pharmaceutical Index, focusing on chemical drugs, biological drugs, and traditional Chinese medicine, complementing the existing medical ETF [4] Group 3 - The medical and pharmaceutical sectors have been in a prolonged adjustment period since 2021, with current valuations potentially offering high cost-effectiveness for investors [4]

证券代码：603456 证券简称：九洲药业 公告编号：2025-036 浙江九洲药业股份有限公司 一、美国 FDA 现场检查的相关情况 关于子公司通过美国 FDA 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江九洲药业股份有限公司（以下简称"公司"）子公司浙江九洲药物科技 有限公司（以下简称"药物科技"）于 2025 年 3 月 17 日至 2025 年 3 月 21 日期 间接受了美国食品药品监督管理局（以下简称"FDA"）的 cGMP（现行药品生 产质量管理规范）现场检查，检查范围涵盖质量体系、物料、生产、包装与标签、 设备设施、实验室控制六大系统。近日，药物科技收到美国 FDA 签发的现场检 查报告（EIR，Establishment Inspection Report），该报告表明药物科技已通过本 次 cGMP 现场检查，现将相关情况公告如下： 公司名称：浙江九洲药物科技有限公司 检查地点：浙江省杭州钱塘新区临江工业园区经六路 1889 号 检查范围：药物科技涉及产品（非无菌原料药阿替洛尔、枸橼酸 ...

Core Viewpoint - The company, Jiuzhou Pharmaceutical, announced that its subsidiary, Zhejiang Jiuzhou Pharmaceutical Technology Co., Ltd., successfully passed the cGMP on-site inspection by the FDA, which will support its expansion into international markets [1] Group 1 - The FDA inspection took place from March 17 to March 21, 2025, covering six major systems [1] - The successful completion of the cGMP inspection indicates compliance with FDA standards, enhancing the company's credibility in the global market [1] - This achievement is expected to positively influence the company's efforts to expand into regulated international markets [1]

Core Viewpoint - The launch of Mashu Lashawei tablets (brand name: Yisuda) by Qingfeng Pharmaceutical Group represents a significant advancement in the treatment of influenza in China, providing a new therapeutic option for clinicians and addressing the challenges of influenza management [1][2]. Group 1: Product Overview - Mashu Lashawei tablets are the first domestically developed PA inhibitor class influenza innovative drug in China, demonstrating unique advantages in combating drug resistance [2]. - The clinical research data from the Phase III trial indicates that the drug effectively inhibits the RNA polymerase PA subunit of the influenza virus, allowing for rapid symptom relief with a single dose throughout the entire treatment course [2]. Group 2: Clinical Implications - The drug has shown good safety and tolerability, with an overall resistance mutation rate of less than 1%, significantly lower than international counterparts targeting the same mechanism [2]. - Current indications do not cover children under 12 years, who are a high-risk group for influenza, highlighting the urgency for further clinical research to include this demographic [2]. Group 3: Future Directions - Qingfeng Pharmaceutical Group plans to advance clinical research for children under 12, conduct resistance testing, and work on insurance directory inclusion to enhance drug accessibility [2].